IL6 and type 2 diabetes mellitus: Secondary endpoints will assess changes in inflammatory biomarkers (tumor necrosis factor-α, interleukin-6), oxidative stress indicators (superoxide dismutase, malondialdehyde), homeostasis model assessment of insulin resistance, insulin sensitivity index, and homeostasis model assessment of β-cell function.<h4>Conclusions</h4>This trial will provide preliminary data on the effects of liraglutide on depressive symptoms in overweight/obese patients with type 2 diabetes.